Mitochondrial and anabolic pathways in hepatocellular carcinoma.
Mitochondrial and anabolic pathways in hepatocellular carcinoma.
复制标题
肝细胞癌中的线粒体和合成代谢途径。
DOI：
10.1002/hep.29559
复制
发表时间：
2018
期刊：
影响因子：
--
通讯作者：
Timchenko,NikolaiA
中科院分区：
文献类型：
--
作者：
Timchenko,NikolaiA
Despite significant improvements in health care in the United States and in the world, liver cancer remains a formidable challenge with limited therapeutic approaches.(1) The development of such approaches is limited by an insufficient understanding of the molecular mechanisms of liver cancer. Hepatocellular carcinoma (HCC) is one of the leading liver cancers that affects many patients of different ages.(1, 2) Numerous mutational studies and studies of global transcriptome and proteome have emphasized extraordinary complexity of alterations that are observed in cancer cells.(3) The liver is a key tissue in metabolic homeostasis regulation, and recent discoveries have shown that certain metabolic alterations are critical in the development of HCC.(2, 3)However, very little is known about the specific mechanisms and key factors that drive the metabolicdependent pathways of HCC. In this issue of HEPATOLOGY, Piccinin et al. have investigated the role of mitochondrial and fatty acid metabolisms in HCC by focusing on a key regulator of these processes: the peroxisome proliferator-activated receptor c (PPARc) co-activator-1b (PGC-1b). This elegant work demonstrates that hepatic PGC-1b drives alterations of the metabolic programs that lead to the development of HCC.(4)
